Amended Statement of Ownership (sc 13g/a)
February 14 2020 - 2:09PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934(Amendment No. 1)*
China
SXT Pharmaceuticals, Inc.
(Name
of Issuer)
Ordinary
Shares, $0.001 par value per share
(Title
of Class of Securities)
G2161P108
(CUSIP
Number)
December
31, 2019
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ]
Rule 13d-1(b)
[X]
Rule 13d-1(c)
[ ]
Rule 13d-1(d)
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
1.
|
NAME
OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Ayrton Capital LLC
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)
[ ]
(b) [ ]
|
3.
|
SEC
USE ONLY
|
4.
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware, U.S.A
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
SOLE
VOTING POWER
2,667,999*
|
6.
|
SHARED
VOTING POWER
0
|
7.
|
SOLE
DISPOSITIVE POWER
2,667,999*
|
8.
|
SHARED
DISPOSITIVE POWER
0
|
9.
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,667,999*
|
10.
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
[ ]
|
11.
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%*
|
12.
|
TYPE
OF REPORTING PERSON (SEE INSTRUCTIONS)
OO
|
1.
|
NAME
OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)
[ ]
(b) [ ]
|
3.
|
SEC
USE ONLY
|
4.
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Cayman Islands
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
SOLE
VOTING POWER
2,667,999*
|
6.
|
SHARED
VOTING POWER
0
|
7.
|
SOLE
DISPOSITIVE POWER
2,667,999*
|
8.
|
SHARED
DISPOSITIVE POWER
0
|
9.
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,667,999*
|
10.
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
[ ]
|
11.
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%*
|
12.
|
TYPE
OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
|
1.
|
NAME
OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Waqas Khatri
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)
[ ]
(b) [ ]
|
3.
|
SEC
USE ONLY
|
4.
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Pakistan
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
SOLE
VOTING POWER
2,667,999*
|
6.
|
SHARED
VOTING POWER
0
|
7.
|
SOLE
DISPOSITIVE POWER
2,667,999*
|
8.
|
SHARED
DISPOSITIVE POWER
0
|
9.
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,667,999*
|
10.
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
[ ]
|
11.
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.99%*
|
12.
|
TYPE
OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
|
Item
1.
|
(a).
|
Name
of Issuer:
|
|
|
|
|
|
China
SXT Pharmaceuticals, Inc. (the “Issuer”)
|
|
|
|
|
(b).
|
Address
of issuer’s principal executive offices:
|
|
|
|
|
|
178
Taidong RD North
|
|
|
Taizhou,
Jiangsu, China
|
|
|
|
Item
2.
|
(a).
|
Name
of person filing:
|
|
|
|
|
|
Ayrton
Capital LLC
|
|
|
Alto
Opportunity Master Fund SPC -Segregated Master Portfolio B
Waqas
Khatri
|
|
|
|
|
|
Address
or principal business office or, if none, residence:
|
|
|
|
|
(b).
|
Ayrton
Capital, LLC
|
|
|
222
Broadway, 19th Floor
|
|
|
New
York, New York 10038
|
|
|
|
|
|
Alto
Opportunity Master Fund, SPC – Segregated Master Portfolio B
|
|
|
222
Broadway, 19th Floor
|
|
|
New
York, New York 10038
|
|
|
Waqas
Khatri
c/o
222 Broadway, 19th Floor
New
York, New York 10038
|
|
|
|
|
(c).
|
Citizenship:
|
|
|
|
|
|
Ayrton
Capital LLC – Delaware
Alto
Opportunity Master Fund SPC – Segregated Master Portfolio B – Delaware
|
|
|
Waqas
Khatri – Pakistan
|
|
|
|
|
(d)
|
Title
of class of securities:
|
|
|
|
|
|
Ordinary
Shares, $0.001 Par Value
|
|
|
|
|
|
CUSIP
No.:
|
|
|
|
|
(e).
|
G2161P108
|
|
|
|
|
|
|
|
|
|
|
|
|
Item
3.
|
If
This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing
is a
N/A
|
Provide
the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in
Item 1.
|
(a)
|
Amount
beneficially owned:
|
Ayrton
Capital LLC – 2,667,999*
Alto
Opportunity Master Fund SPC – Segregated Master Portfolio B – 2,667,999*
Waqas
Khatri – 2,667,999*
Ayrton
Capital LLC – 9.99%*
Alto
Opportunity Master Fund SPC – Segregated Master Portfolio B – 9.99%*
Waqas
Khatri – 9.99 %*
|
(c)
|
Number
of shares as to which Ayrton Capital LLC has:
|
|
(i)
|
Sole
power to vote or to direct the vote
|
|
2,667,999*
|
,
|
|
|
|
|
|
|
|
(ii)
|
Shared
power to vote or to direct the vote
|
|
0
|
*,
|
|
|
|
|
|
|
|
(iii)
|
Sole
power to dispose or to direct the disposition of
|
|
2,667,999*
|
,
|
|
|
|
|
|
|
|
(iv)
|
Shared
power to dispose or to direct the disposition of
|
|
0
|
.
|
|
|
|
|
|
|
|
Number
of shares as to which has: Alto Opportunity Master Fund SPC – Segregated Master Portfolio B
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Sole
power to vote or to direct the vote
|
|
2,667,999*
|
,
|
|
|
|
|
|
|
|
(ii)
|
Shared
power to vote or to direct the vote
|
|
0
|
,
|
|
|
|
|
|
|
|
(iii)
|
Sole
power to dispose or to direct the disposition of
|
|
2,667,999*
|
,
|
|
|
|
|
|
|
|
(iv)
|
Shared
power to dispose or to direct the disposition of
|
|
0
|
.
|
|
|
|
|
|
|
|
Number
of shares as to which Waqas Khatri has:
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Sole
power to vote or to direct the vote
|
|
2,667,999*
|
,
|
|
|
|
|
|
|
|
(ii)
|
Shared
power to vote or to direct the vote
|
|
0
|
,
|
|
|
|
|
|
|
|
(iii)
|
Sole
power to dispose or to direct the disposition of
|
|
2,667,999*
|
,
|
|
|
|
|
|
|
|
(iv)
|
Shared
power to dispose or to direct the disposition of
|
|
0
|
.
|
*
The ordinary shares, $0.001 par value (the “Shares”) of China SXT Pharmaceuticals, Inc. (the “Company”),
reported herein are held by Alto Opportunity Master Fund SPC – Segregated Master Portfolio B (the “Fund”), which
are managed by Ayrton Capital LLC (the “Adviser”) and consist of (a) 2,000,000 ordinary shares plus (b) 667,999 warrants
and convertible notes, which are exercisable and convertible into ordinary shares on a one-for-one basis. Accordingly, for purposes
of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially own an aggregate of 2,667,999 Shares, or 9.99% of the Shares
issued and outstanding as of November 5, 2019. Waqas Khatri is the Managing member of the Adviser. The beneficial ownership percentage
reported herein is based on 26,706,701 Shares issued and outstanding as of November 5, 2019, as disclosed in the Company’s
Prospectus as filed with the Securities and Exchange Commission on November 5, 2019, and includes 667,999 warrants and convertible
notes, exercisable/convertible into ordinary shares on a one-for-one basis and are exercisable/convertible within 60 days of December
31, 2019. This report shall not be deemed an admission that the Adviser, the Funds or any other person is the beneficial owner
of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other
purpose. Each of the reporting persons herein disclaims beneficial ownership of the Shares reported herein except to the extent
of the reporting person’s pecuniary interest therein.
|
Item
5.
|
Ownership
of Five Percent or Less of a Class.
|
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following.
N/A
Item
6.
|
Ownership
of More Than Five Percent on Behalf of Another Person.
|
If
any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from
the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates
to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company
registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund
is not required.
N/A
Item
7.
|
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control
Person.
|
If
a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item
3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding
company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification
of the relevant subsidiary.
N/A
Item
8.
|
Identification
and Classification of Members of the Group.
|
If
a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating
the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d- 1(c)
or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
N/A
Item
9.
|
Notice
of Dissolution of Group.
|
Notice
of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with
respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.
See Item 5.
N/A
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated:
February 14, 2020
|
Ayrton
Capital LLC
|
|
|
|
|
By:
|
/s/
Waqas Khatri
|
|
Name:
|
Waqas
Khatri
|
|
Title:
|
Managing
Member
|
|
|
|
|
Alto
Opportunity Master Fund SPC – Segregated Master Portfolio B
|
|
|
|
|
By:
|
/s/
Waqas Khatri
|
|
Name:
|
Waqas
Khatri
|
|
Title:
|
Managing
Member
|
|
|
|
|
Ayrton
Capital LLC
|
|
|
|
By
|
Waqas
Khatri
|
|
|
|
|
By:
|
/s/
Waqas Khatri
|
|
Name:
|
Waqas
Khatri
|
|
Title:
|
Managing
Member
|
The
original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If
the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner
of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the
statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated
by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
Note.
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7
for other parties for whom copies are to be sent.
Attention.
Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).
China SXT Pharmaceuticals (NASDAQ:SXTC)
Historical Stock Chart
From Jan 2025 to Feb 2025
China SXT Pharmaceuticals (NASDAQ:SXTC)
Historical Stock Chart
From Feb 2024 to Feb 2025